Rubi K. Li

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 503 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

E. Donnall Thomas, Henry Gómez, Rubi K. Li et al. · Journal of Clinical Oncology · 2007 · 483 citations · Full text

Medicine, Oncology, Pharmacology +11

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Justin Stebbing, Y. Baranau, Valeriy Baryash et al. · The Lancet Oncology · 2017 · 123 citations · Full text

Medicine, Oncology, Breast Oncology +13

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

Gabriel N. Hortobágyi, Henry Gómez, Rubi K. Li et al. · Breast Cancer Research and Treatment · 2010 · 66 citations · Full text

Medicine, Oncology, Pharmacology +11

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

Mark D. Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto et al. · British Journal of Cancer · 2018 · 60 citations · Full text

Medicine, Oncology, Pharmacology +15